other material
confidence high
sentiment positive
materiality 0.80
Zevra sells PRV for $150M cash; funds MIPLYFFA & OLPRUVA launches
ZEVRA THERAPEUTICS, INC.
- Gross proceeds of $150M, payable in cash at closing; expected within 30-45 days.
- PRV granted in Sep 2024 upon FDA approval of MIPLYFFA for Niemann-Pick type C.
- Transaction subject to HSR waiting period expiration; Cantor Fitzgerald advised.
- CFO states non-dilutive capital strengthens balance sheet, supports commercial launches and pipeline.